AMR Evidence-Status Framework
01
Established Specifications
Confirmed structural identity and measured data verifying physicochemical context via primary literature and available analytical records.
02
Mechanistic Review
Evidence assessment of signaling pathways based on preclinical findings and secondary synthesis data.
03
Evaluation of technical dossiers using computational/model-derived estimates and available HPLC/MS analytical records.
Verification of technical dossiers using computational/model-derived estimates and raw HPLC/MS records.
04
Supported Synthesis
Documentation distinguishing validated preclinical evidence from a preliminary Mechanistic Hypothesis.
Evidence Catalog
Compound Directory
Incretin Analogs
Semaglutide & Tirzepatide
Supported metabolic regulators analyzed through measured data. Records include primary literature synthesis, validated molecular sequences, and HPLC verification files.
GH-Secretagogues
Sermorelin & CJC-1295
Preliminary signaling peptides for nonclinical use. Dossiers categorize Preclinical evidence vs Evidence Gaps regarding specific signaling mechanisms.
Immunomodulatory Analogs
BPC-157 & KPV
Modeled substances in laboratory settings. Reports delineate Mechanistic findings from interspecies extrapolation and Hypothesis stages.
Analytical Evidence Rigor
01
Measured Data Standards
AMR evaluates available HPLC/MS analytical records and primary biochemical literature when assessing compound identity and specifications. Only evidence appropriate to the specific claim is treated as Established.
02
Classification Divisions
Our synthesis separates Supported findings from Preliminary models. Insights are systematically audited to isolate a Mechanistic Hypothesis from established animal data or interspecies extrapolation results.
03
Status Validation Audits
All entries undergo rigorous audits to address Evidence Gaps and maintain institutional standards. Each report delineates verified boundaries, strictly excluding therapeutic claims or any clinical health interpretations.